Bioatla, Inc. earnings releases BCAB

Annual Quarterly

Bioatla, Inc. last reported quarterly results on Mar 2, 2026, for Q4 FY2025 (the quarter ended Dec 31, 2025): diluted EPS of -$0.16. It usually reports 36–61 days after a quarter ends.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 36–61 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released	Quarter	Revenue	Net income	Diluted EPS
Mar 2, 2026 61 days after quarter end	Q4 FY2025 ended Dec 31, 2025	—	-10 +34.3%	-0.16 +45.4%
Nov 13, 2025 44 days after quarter end	Q3 FY2025 ended Sep 30, 2025	—	-16 -49.0%	-0.27 -22.7%
Aug 7, 2025 38 days after quarter end	Q2 FY2025 ended Jun 30, 2025	—	-19 +11.2%	-15.99 -3534.1%
May 6, 2025 36 days after quarter end	Q1 FY2025 ended Mar 31, 2025	—	-15 +34.0%	-13.16 -2641.7%
Nov 7, 2024 38 days after quarter end	Q3 FY2024 ended Sep 30, 2024	—	-11 +68.2%	-0.22 +68.6%
Aug 8, 2024 39 days after quarter end	— ended Jun 30, 2024	—	—	—
May 14, 2024 44 days after quarter end	— ended Mar 31, 2024	—	—	—
Nov 7, 2023 38 days after quarter end	— ended Sep 30, 2023	—	—	—

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: BCAB (OTC)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: San Diego, CA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1826892

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.